Related Experiment Video

Updated: Oct 29, 2025

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma
12:24

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma

Published on: September 30, 2021

5.6K

Targeting Long Non-Coding RNAs in Hepatocellular Carcinoma: Progress and Prospects

Xinrong Lin1, Xiaosong Xiang2, Bing Feng1

  • 1Department of Medical Oncology, Affiliated Jinling Hospital, Medical School of Nanjing University, Nanjing, China.

Frontiers in Oncology
|July 12, 2021
PubMed

Insights

Long non-coding RNAs (lncRNAs) show abnormal expression in hepatocellular carcinoma, impacting tumor progression and treatment resistance. Targeting lncRNAs offers a promising strategy for improving patient survival in liver cancer.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Hepatocellular carcinoma (HCC) is a major global cancer with poor prognosis.
  • Aberrant expression of long non-coding RNAs (lncRNAs) is observed in various cancers, including HCC.
  • lncRNAs play critical roles in cellular processes relevant to cancer development.

Conclusions:

  • lncRNAs are crucial regulators in hepatocellular carcinoma pathogenesis.
  • Targeting lncRNAs presents a promising avenue for novel HCC therapies.
  • Understanding lncRNA functions can enhance treatment strategies for liver cancer.
Keywords:
clinical transformationhepatocellular carcinomalong non-coding RNAsignaling pathwaytherapy resistance

More Related Videos

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis06:38

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

9.1K
Author Spotlight: Investigating Liver Cancer Pathogenesis Using Patient-Derived Organoids07:25

Author Spotlight: Investigating Liver Cancer Pathogenesis Using Patient-Derived Organoids

Published on: August 18, 2023

2.1K

Related Concept Videos

lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
9.2K
lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

3.0K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.0K